Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP28 | Q96RU2 | 1/20 | 0.33 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16437902 | 0.81 | LMNA (0.35) | PTGDR2PTPN7DUSP3 | |
| SCHEMBL16437899 | 0.79 | APLNR (0.37) | PTGDR2MAPT | |
| SCHEMBL247850 | 0.72 | DGAT1 (0.37) | USP28USP25PTGDR2PTPN7DUSP3 | |
| SCHEMBL360810 | 0.72 | DGAT1 (0.37) | USP28USP25PTGDR2PTPN7DUSP3 | |
| SCHEMBL360811 | 0.72 | DGAT1 (0.37) | USP28USP25PTGDR2PTPN7DUSP3 | |
| SCHEMBL1173372 | 0.72 | DGAT1 (0.37) | USP28USP25PTGDR2PTPN7DUSP3 | |
| SCHEMBL1173257 | 0.72 | DGAT1 (0.37) | USP28USP25PTGDR2PTPN7DUSP3 | |
| SCHEMBL17004584 | 0.72 | USP28 (0.34) | USP28USP25PTGDR2PTPN7DUSP3 | |
| SCHEMBL15963925 | 0.72 | DGAT1 (0.34) | PTGDR2MAPTAAK1 | |
| SCHEMBL17004586 | 0.72 | USP28 (0.34) | USP28USP25PTGDR2PTPN7DUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150252059-A1 | BRIDGED BICYCLIC AMINO THIAZINE DIOXIDE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF | AMGEN INC (US) | 2015-09-10 | — | — | US | disclosed |
| US-9096615-B2 | Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta-secretase and methods of use thereof | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150038497-A1 | BRIDGED BICYCLIC AMINO THIAZINE DIOXIDE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF | AMGEN INC. | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252059-A1 | BRIDGED BICYCLIC AMINO THIAZINE DIOXIDE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF | BACE1, BACE2, APP | USP28 3087/4885USP25 3969/4885PTGDR2 1424/4885 |
| US-20150038497-A1 | BRIDGED BICYCLIC AMINO THIAZINE DIOXIDE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF | BACE1, BACE2, APP | USP28 3087/4885USP25 3969/4885PTGDR2 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.